Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

The revolutionary test has been shown in trials to diagnose pancreatic cancer even before patients have symptoms. Researchers say the test costs less than a penny per patient, and could improve ...

Treatment with a cold atmospheric plasma reduced the recurrence rate of melanoma tumours after surgery by roughly 50% ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.